Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RASolve 301: Daraxonrasib vs docetaxel in previously treated RAS-mutated NSCLC
2024-518154-16-00Phase 3Authorised
- Sponsor
- Revolution Medicines
- Start
- Aug 2025
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of daraxonrasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Revolution Medicines. Primary endpoints: Progression-free survival (PFS) and Overall survival (OS). Planned start Aug 2025; status: authorised.
02
Drugs
daraxonrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-518154-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518154-16-00.